A study to assess the pharmacokinetics of LCZ696 in subjects with hepatic impairment compared to matched healthy subjects

Femme et Homme

| Pays :
| Organes :
| Spécialités :

Extrait

This is a study to characterize the pharmacokinetics as well as safety and tolerability of a single oral dose of LCZ696 200 mg in subjects with mild and moderate hepatic impairment compared to matched healthy subjects.

Critère d'inclusion

Mild and moderate hepatic impairment

Liens

ictrp
euctr